Suppr超能文献

原发性骨髓纤维化小鼠模型揭示造血干细胞与其微环境之间的病理相互作用。

Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

作者信息

Varricchio Lilian, Mancini Annalisa, Migliaccio Anna Rita

机构信息

Department of Medicine, Division of Hematology/Oncology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1079, New York, NY 10029, USA Tel.: +1 212 241 6974

出版信息

Expert Rev Hematol. 2009 Jun 1;2(3):315-334. doi: 10.1586/ehm.09.17.

Abstract

Primary myelofibrosis (PMF) belongs to the Philadelphia-negative myeloproliferative neoplasms and is a hematological disorder caused by abnormal function of the hematopoietic stem cells. The disease manifests itself with a plethora of alterations, including anemia, splenomegaly and extramedullary hematopoiesis. Its hallmarks are progressive marrow fibrosis and atypical megakaryocytic hyperplasia, two distinctive features used to clinically monitor disease progression. In an attempt to investigate the role of abnormal megakaryocytopoiesis in the pathogenesis of PMF, several transgenic mouse models have been generated. These models are based either on mutations that interfere with the extrinsic (thrombopoietin and its receptor, MPL) and intrinsic (the GATA1 transcription factor) control of normal megakaryocytopoiesis, or on known genetic lesions associated with the human disease. Here we provide an up-to-date review on the insights into the pathobiology of human PMF achieved by studying these animal models, with particular emphasis on results obtained with Gata1(low) mice.

摘要

原发性骨髓纤维化(PMF)属于费城染色体阴性的骨髓增殖性肿瘤,是一种由造血干细胞功能异常引起的血液系统疾病。该疾病表现为多种改变,包括贫血、脾肿大和髓外造血。其特征是进行性骨髓纤维化和非典型巨核细胞增生,这是用于临床监测疾病进展的两个显著特征。为了研究异常巨核细胞生成在PMF发病机制中的作用,已经建立了几种转基因小鼠模型。这些模型要么基于干扰正常巨核细胞生成的外在(血小板生成素及其受体MPL)和内在(GATA1转录因子)控制的突变,要么基于与人类疾病相关的已知基因损伤。在此,我们提供了一篇最新综述,介绍通过研究这些动物模型对人类PMF病理生物学的深入了解,特别强调了Gata1(low)小鼠的研究结果。

相似文献

2
P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.
Stem Cells. 2016 Jan;34(1):67-82. doi: 10.1002/stem.2229. Epub 2015 Oct 23.
3
Novel targets to cure primary myelofibrosis from studies on Gata1 mice.
IUBMB Life. 2020 Jan;72(1):131-141. doi: 10.1002/iub.2198. Epub 2019 Nov 21.
4
Primary myelofibrosis: update on definition, pathogenesis, and treatment.
Annu Rev Med. 2009;60:233-45. doi: 10.1146/annurev.med.60.041707.160528.
5
[Pathogenesis and Targeted Treatment Progress of Splenomegaly in Primary Myelofibrosis--Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Feb;32(1):308-312. doi: 10.19746/j.cnki.issn.1009-2137.2024.01.050.
7
Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.
Stem Cell Investig. 2016 Feb 26;3:5. doi: 10.3978/j.issn.2306-9759.2016.02.03. eCollection 2016.
10
Myelofibrosis: experimental models and human studies.
Stem Cells. 1998;16 Suppl 2:155-64. doi: 10.1002/stem.5530160718.

引用本文的文献

1
New Markers of Disease Progression in Myelofibrosis.
Cancers (Basel). 2021 Oct 23;13(21):5324. doi: 10.3390/cancers13215324.
2
Captopril mitigates splenomegaly and myelofibrosis in the Gata1 murine model of myelofibrosis.
J Cell Mol Med. 2018 Sep;22(9):4274-4282. doi: 10.1111/jcmm.13710. Epub 2018 Jul 4.
3
HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis.
Nat Commun. 2018 Apr 12;9(1):1431. doi: 10.1038/s41467-018-03627-9.
4
Efficacy of ALK5 inhibition in myelofibrosis.
JCI Insight. 2017 Apr 6;2(7):e90932. doi: 10.1172/jci.insight.90932.
5
The role of the extracellular matrix in primary myelofibrosis.
Blood Cancer J. 2017 Feb 3;7(2):e525. doi: 10.1038/bcj.2017.6.
6
In vivo magnetic resonance imaging of a mouse model of myelofibrosis.
Blood Cancer J. 2016 Nov 11;6(11):e497. doi: 10.1038/bcj.2016.97.
7
Acute Myeloid Leukemia with Isolated Trisomy 19 Associated with Diffuse Myelofibrosis and Osteosclerosis.
Cancers (Basel). 2015 Dec 14;7(4):2459-65. doi: 10.3390/cancers7040903.
9
Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche.
Cell Stem Cell. 2013 Sep 5;13(3):285-99. doi: 10.1016/j.stem.2013.06.009. Epub 2013 Jul 11.
10
Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.
Blood. 2013 Apr 25;121(17):3345-63. doi: 10.1182/blood-2012-06-439661. Epub 2013 Mar 5.

本文引用的文献

1
Normal bone anatomy and physiology.
Clin J Am Soc Nephrol. 2008 Nov;3 Suppl 3(Suppl 3):S131-9. doi: 10.2215/CJN.04151206.
2
Primary myelofibrosis: update on definition, pathogenesis, and treatment.
Annu Rev Med. 2009;60:233-45. doi: 10.1146/annurev.med.60.041707.160528.
3
Platelets, petechiae, and preservation of the vascular wall.
N Engl J Med. 2008 Sep 18;359(12):1261-70. doi: 10.1056/NEJMra0800887.
4
Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
Cancer Genet Cytogenet. 2008 Oct;186(1):6-11. doi: 10.1016/j.cancergencyto.2008.04.021.
6
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28.
7
Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells.
Blood. 2008 Nov 15;112(10):4039-47. doi: 10.1182/blood-2008-05-154849. Epub 2008 Aug 27.
8
Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway.
Cell Signal. 2008 Nov;20(11):1995-2001. doi: 10.1016/j.cellsig.2008.07.008. Epub 2008 Jul 17.
9
G-CSF stimulates Jak2-dependent Gab2 phosphorylation leading to Erk1/2 activation and cell proliferation.
Cell Signal. 2008 Oct;20(10):1890-9. doi: 10.1016/j.cellsig.2008.06.018. Epub 2008 Jul 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验